Tune Therapeutics
Luis Sanchez-Perez has over 10 years of work experience in the field of preclinical translation. Luis is currently the Director of Preclinical Translation at Tune Therapeutics, a position they have held since 2020. Prior to this, they were the Associate Director of Preclinical Translation at Tune Therapeutics. From 2008 to 2020, they were an Assistant Professor at Duke University, where they were responsible for elucidating the mechanisms of “armored” CAR mediated rejection of heterogeneous brain tumors and designing pre-clinical mouse studies focused on novel immuno-therapeutic approaches against experimental brain tumors. From 2006 to 2008, they were a Research Scientist and Senior Research Associate at the National Cancer Institute, where they evaluated the role of Temozolomide mediated host conditioning on T-cell based immunotherapy against brain tumors and elucidated the mechanisms associated with the induction of supraphysiological levels of antigen-specific antibodies and TMZ-induced lymphopenia.
Luis Sanchez-Perez earned their Doctorate in Immunology from the Mayo Clinic School of Medicine between 2000 and 2006. Prior to that, they obtained a Bachelor of Science in Industrial Biotechnology from the University of Puerto Rico-Mayaguez between 1995 and 2000.
This person is not in any offices
Tune Therapeutics
1 followers
With its versatile and powerful TEMPO epigenomic control platform, Tune Therapeutics is pioneering a new therapeutic modality that can fine-tune any gene network and unlock the full power and potential of regenerative medicine. With deep experience and a passionate commitment to exploration and innovation, Tune is driving through an inflection point in the history of genetic medicine: from targeting a limited range of rare conditions, to addressing thousands of common and complex diseases for which no curative treatment is available.